Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
Triple-negative breast cancer (TNBC) remains a cancer of significant unmet need, with limited treatment options beyond systemic chemotherapy. Recently, TROP2 has emerged as a target of interest, and antibody-drug conjugates (ADCs) targeting TROP2 can provide substantial clinical benefit to patients with TNBC. However, physicians who incorporate treatments that exploit TROP2 must navigate practical challenges of treating the disease and managing adverse events.
In this dynamic tumor board program, expert faculty address these issues and guide structured discussions on the latest evidence surrounding the role of TROP2-targeted therapies and ADC-sequencing strategies for the treatment of TNBC. Through education, clinicians will be better equipped to provide quality care and optimize outcomes for their patients with TNBC. This program took place in conjunction with the 24th Annual International Congress on the Future of Breast Cancer®—East conference.
This educational activity is an archive of the live virtual symposium held on July 11, 2025.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of TNBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety data from clinical trials evaluating TROP2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
- Integrate TROP2-targeted ADCs into individualized treatment plans for patients with TNBC
- Discuss disparities in care among diverse populations of patients with TNBC, including potential root causes and regional differences in attitudes and practice patterns
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here